Hla-g as a novel target for car t-cell immunotherapy
AssigneeUniversity of Southern California
InventorsAlan L. Epstein, Peisheng Hu
Life of this patent
Estimating the term…
Abstract
CAR cells targeting and antibodies human HLA-G are described as a new method of cancer treatment. It is proposed that HLA-G CAR cells are safe and effective in patients and can be used to treat human tumors expressing the HLA-G.
Claims36
An isolated antibody comprising a heavy chain (HC) immunoglobulin variable domain sequence and a light chain (LC) immunoglobulin variable domain sequence, wherein the antibody binds to an epitope of HLA-G comprising the amino acid sequence SEQ ID NO:
- 30, or an equivalent thereof, wherein the HC immunoglobulin variable domain sequence comprises a CDRH1 sequence comprising GFNIKDTY (SEQ ID NO:
- 1) or GFTFNTYA (SEQ ID NO:
- 2) or an equivalent of each thereof, a CDRH2 sequence comprising IDPANGNT (SEQ ID NO:
- 3) or IRSKSNNYAT (SEQ ID NO:
- 4) or an equivalent of each thereof, and a CDRH3 sequence comprising ARSYYGGFAY (SEQ ID NO:
- 5) or VRGGYWSFDV (SEQ ID NO:
- 6) or an equivalent of each thereof, wherein the LC immunoglobulin variable domain sequence comprises a CDRL1 sequence comprising KSVSTSGYSY (SEQ ID NO:
- 11) or KSLLHSNGNTY (SEQ ID NO:
- 12) or an equivalent of each thereof, a CDRL2 sequence comprising LVS (SEQ ID NO:
- 13) or RMS (SEQ ID NO:
- 14) or an equivalent of each thereof, a CDRL3 sequence comprising QHSRELPRT (SEQ ID NO:
- 15) or MQHLEYPYT (SEQ ID NO:
- 16) or an equivalent of each thereof, wherein an equivalent has at least 80% amino acid identity to the sequence, or is encoded by a polynucleotide that is at least 80% identical to a polynucleotide encoding the sequence.
2-8. (canceled)
(canceled)
(canceled)
(canceled)
17-20. (canceled)
22-27. (canceled)
31-33. (canceled)
(canceled)
37-42. (canceled)
44-45. (canceled)
(canceled)
(canceled)
(canceled)
54-57. (canceled)
59-62. (canceled)
A method for determining if a patient is likely to respond or is not likely to HLA-G CAR therapy, comprising contacting a tumor sample isolated from the patient with an effective amount of an anti-HLA-G antibody and detecting the presence of any antibody bound to the tumor sample, wherein the presence of antibody bound to the tumor sample indicates that the patient is likely to respond to the HLA-G CAR therapy and the absence of antibody bound to the tumor sample indicates that the patient is not likely to respond to the HLA-G therapy.
(canceled)
Dependencies are inferred from the claim text.